This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Trail, P. A. Articles by Braslawsky, G. R. Search for Related Content PubMed PubMed Citation Articles by Trail, P. A. Articles by Braslawsky, G. R.

Antigen-specific Activity of Carcinoma-reactive BR64-Doxorubicin Conjugates Evaluated in Vitro and in Human Tumor Xenograft Models

Department of Experimental Therapeutics [P. A. T., S. J. L., A. J. H.], Department of Immunology [R. S. G., M. E. Z., G. R. B.], and Department of Chemistry [D. W., D. K.], Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492

The anticarcinoma antibody BR64 was conjugated to a doxorubicin derivative, doxorubicin 13-[3-(2-pyridyldithio)propionyl]hydrazone, and the resulting conjugates (BR64-DOX) were evaluated for activity and immunological specificity in vitro and in human tumor xenograft models. The BR64-DOX immunoconjugates retained immunoreactivity and cytotoxicity and demonstrated antigen-specific cytotoxicity in vitro. The potency of BR64-DOX immunoconjugates in vitro was related to the drug:monoclonal antibody mole ratio of the conjugates. The antitumor activity of BR64-DOX conjugates was consistently superior to the maximal activity obtained with the parent drug, doxorubicin (DOX), in established human lung and human breast carcinoma xenograft models. The superior antitumor activity of BR64-DOX conjugates was reflected both in tumor growth inhibition and in regressions and cures of established tumors following the administration of tolerated doses of BR64-DOX. The antitumor activity of BR64-DOX conjugates was not the result of synergism between monoclonal antibody BR64 and DOX, because mixtures consisting of monoclonal antibody and optimized DOX were not more active than an equivalent dose of DOX administered alone. The antitumor activity of BR64-DOX conjugates was antigen specific; equivalent doses of nonbinding isotype-matched conjugates were not active against established tumor xenografts.

¹ To whom requests for reprints should be addressed, at Bristol-Myers Squibb Pharmaceutical Research Institute, P.O. Box 4000, Princeton, NJ 08543-4000.

Received 4/21/92. Accepted 8/ 5/92.

This article has been cited by other articles:

				J. Yang, H. Chen, I. R. Vlahov, J.-X. Cheng, and P. S. Low Characterization of the pH of Folate Receptor-Containing Endosomes and the Rate of Hydrolysis of Internalized Acid-Labile Folate-Drug Conjugates J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 462 - 468. [Abstract] [Full Text] [PDF]

				K. Inoh, H. Muramatsu, S. Torii, S. Ikematsu, M. Oda, H. Kumai, S. Sakuma, T. Inui, T. Kimura, and T. Muramatsu Doxorubicin-Conjugated Anti-Midkine Monoclonal Antibody as a Potential Anti-Tumor Drug Jpn. J. Clin. Oncol., April 1, 2006; 36(4): 207 - 211. [Abstract] [Full Text] [PDF]

				M. N. Saleh, S. Sugarman, J. Murray, J. B. Ostroff, D. Healey, D. Jones, C. R. Daniel, D. LeBherz, H. Brewer, N. Onetto, et al. Phase I Trial of the Anti-Lewis Y Drug Immunoconjugate BR96-Doxorubicin in Patients With Lewis Y-Expressing Epithelial Tumors J. Clin. Oncol., June 11, 2000; 18(11): 2282 - 2292. [Abstract] [Full Text] [PDF]

				P. Trail, D Willner, S. Lasch, A. Henderson, S Hofstead, A. Casazza, R. Firestone, I Hellstrom, and K. Hellstrom Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates Science, July 9, 1993; 261(5118): 212 - 215. [Abstract] [PDF]